세계의 제네릭 주사제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2033년)
Global Generic Injectables Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
상품코드:1820516
리서치사:Value Market Research
발행일:2025년 09월
페이지 정보:영문 159 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 제네릭 주사제 시장은 2024년 1,401억 9,000만 달러에서 2033년에는 4,158억 1,000만 달러에 이르며 대폭적인 성장이 전망됩니다. 2025-2033년 연평균 복합 성장률(CAGR)은 12.84%에 이를 것으로 예측됩니다.
세계 제네릭 주사제 시장은 암, 항감염증, 심혈관 질환 등의 치료 영역에서 비용 효율적이고 접근성이 높은 주사제에 대한 수요가 증가함에 따라 강력한 성장세를 보이고 있습니다. 만성질환 및 급성질환의 유병률 증가와 브랜드 주사제의 특허만료가 맞물려 제네릭 주사제 분야가 확대되고 있습니다. 동결건조, 프리필드시린지 등 제제기술의 발전으로 제품의 안정성, 안전성, 환자 순응도가 향상되고 있습니다. 바이오시밀러 의약품과 제네릭 의약품의 승인을 촉진하는 규제 프레임워크는 시장 진입과 경쟁을 촉진하고 있습니다.
특히 신흥 시장에서는 병원과 외래에서 주사 요법의 채택이 증가하고 있으며, 이는 수요를 촉진하고 있습니다. 무균 제조, 품질 관리, 공급망 최적화에 중점을 둔 제조 기술 혁신으로 제품의 가용성과 가격이 향상되었습니다. 또한, 코로나19 사태로 인해 주사제 치료제의 중요성이 부각되면서 시장 성장에 가속도가 붙고 있습니다. 제약회사와 CMO(위탁생산기관)의 전략적 파트너십은 생산 능력과 기술 혁신을 강화하고 있습니다.
헬스케어 시스템이 비용 절감과 접근성 확대에 중점을 두고 있는 가운데, 제네릭 주사제 시장은 지속적으로 확대되고 있으며, 전 세계적으로 저렴한 가격에 고품질의 주사제 치료제를 제공합니다.
목차
제1장 서문
제2장 주요 요약
시장 하이라이트
세계 시장 현황
제3장 제네릭 주사제 - 산업 분석
서론 : 시장 역학
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
업계 동향
Porter의 Five Forces 분석
시장 매력 분석
제4장 밸류체인 분석
밸류체인 분석
원재료 분석
원재료 리스트
원재료 제조업체 리스트
주요 원재료 가격 동향
잠재적 바이어 리스트
마케팅 채널
직접 마케팅
간접 마케팅
마케팅 채널 발전 동향
제5장 세계의 제네릭 주사제 시장 분석 : 제품 유형별
개요 : 제품 유형별
과거 및 예측 데이터 분석 : 제품 유형별
고분자 주사제
저분자 주사제
제6장 세계의 제네릭 주사제 시장 분석 : 용도별
개요 : 용도별
과거 및 예측 데이터 분석 : 용도별
종양학
감염증
순환기
당뇨병
면역학
기타
제7장 세계의 제네릭 주사제 시장 분석 : 용기 유형별
용기 유형별 개요
과거 및 예측 데이터 분석 : 용기 유형별
바이알
프리믹스
프리필드 시린지
앰플
기타
제8장 세계의 제네릭 주사제 시장 분석 : 투여 경로별
투여 경로별 개요
과거 및 예측 데이터 분석 : 투여 경로별
정맥내
근육내
피하 주사
기타
제9장 세계의 제네릭 주사제 시장 분석 : 지역별
지역별 전망
서론
북미의 판매 분석
개요, 분석과 예측
북미 : 부문별
북미 국가별
미국
캐나다
멕시코
유럽의 판매 분석
개요, 분석과 예측
유럽 : 부문별
유럽 국가별
영국
프랑스
독일
이탈리아
러시아
기타 유럽
아시아태평양의 판매 분석
개요, 분석과 예측
아시아태평양 : 부문별
아시아태평양 국가별
중국
인도
일본
한국
호주
동남아시아
기타 아시아태평양
라틴아메리카의 판매 분석
개요, 분석과 예측
라틴아메리카 : 부문별
라틴아메리카 국가별
브라질
아르헨티나
페루
칠레
기타 라틴아메리카
중동 및 아프리카의 판매 분석
개요, 분석과 예측
중동 및 아프리카 : 부문별
중동 및 아프리카 국가별 리스트
사우디아라비아
아랍에미리트(UAE)
이스라엘
남아프리카공화국
기타 중동 및 아프리카
제10장 제네릭 주사제기업 경쟁 구도
제네릭 주사제시장 경쟁
제휴, 협력 및 합의
인수합병(M&A)
신제품 출시
기타 개발
제11장 기업 개요
주요 기업의 시장 점유율 분석
시장 집중도
AstraZeneca
Baxter International Inc.
Biocon
Fresenius SE & Co. KGaA
GlaxoSmithKline Plc
Hikma Pharmaceuticals Plc
Johnson & Johnson Services Inc.
Lupin Ltd.
Merck KGaA
Mylan N.V.
Novartis AG(Sandoz International GmbH)
Pfizer Inc.
Piramal Pharma Solutions
Sun Pharmaceutical Industries Ltd.
And Teva Pharmaceutical Industries Ltd
LSH
영문 목차
영문목차
Global Generic Injectables Market is poised to witness substantial growth, reaching a value of USD 415.81 Billion by the year 2033, up from USD 140.19 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 12.84% between 2025 and 2033.
The global generic injectables market is witnessing robust growth driven by increasing demand for cost-effective and accessible injectable medications across therapeutic areas such as oncology, anti-infectives, and cardiovascular diseases. The rising prevalence of chronic and acute conditions, coupled with patent expirations of branded injectables, is expanding the generic injectables segment. Advances in formulation technologies, including lyophilization and prefilled syringes, are enhancing product stability, safety, and patient compliance. Regulatory frameworks promoting biosimilar and generic drug approvals are facilitating market entry and competition.
The growing adoption of hospital and outpatient injectable therapies, especially in emerging markets, is fueling demand. Manufacturing innovations focusing on sterile production, quality control, and supply chain optimization are improving product availability and affordability. Additionally, the COVID-19 pandemic has underscored the importance of injectable therapeutics, accelerating market growth. Strategic partnerships between pharmaceutical companies and contract manufacturing organizations (CMOs) are enhancing capacity and innovation.
As healthcare systems emphasize cost containment and expanded access, the generic injectables market is poised for sustained expansion, delivering affordable and high-quality injectable therapies globally.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
LIST OF SEGMENTS COVERED
This section of the Generic Injectables market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product Type
Large Molecule Injectables
Small Molecule Injectables
By Application
Oncology
Infectious Diseases
Cardiology
Diabetes
Immunology
Others
By Container Type
Vials
Premix
Prefilled Syringes
Ampoules
Others
By Route of Administration
Intravenous
Intramuscular
Subcutaneous
Others
List of Companies Profiled in the report
AstraZeneca, Baxter International Inc., Biocon, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Lupin Ltd., Merck KGaA, Mylan N.V., Novartis AG (Sandoz International GmbH), Pfizer Inc., Piramal Pharma Solutions, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.1 Market Attractiveness Analysis By Product Type
3.7.2 Market Attractiveness Analysis By Application
3.7.3 Market Attractiveness Analysis By Container Type
3.7.4 Market Attractiveness Analysis By Route of Administration
3.7.5 Market Attractiveness Analysis By Regions
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY PRODUCT TYPE
5.1. Overview By Product Type
5.2. Historical and Forecast Data Analysis By Product Type
5.3. Large Molecule Injectables Historic and Forecast Sales By Regions
5.4. Small Molecule Injectables Historic and Forecast Sales By Regions
6. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY APPLICATION
6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Oncology Historic and Forecast Sales By Regions
6.4. Infectious Diseases Historic and Forecast Sales By Regions
6.5. Cardiology Historic and Forecast Sales By Regions
6.6. Diabetes Historic and Forecast Sales By Regions
6.7. Immunology Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions
7. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY CONTAINER TYPE
7.1. Overview By Container Type
7.2. Historical and Forecast Data Analysis By Container Type
7.3. Vials Historic and Forecast Sales By Regions
7.4. Premix Historic and Forecast Sales By Regions
7.5. Prefilled Syringes Historic and Forecast Sales By Regions
7.6. Ampoules Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions
8. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
8.1. Overview By Route of Administration
8.2. Historical and Forecast Data Analysis By Route of Administration
8.3. Intravenous Historic and Forecast Sales By Regions
8.4. Intramuscular Historic and Forecast Sales By Regions
8.5. Subcutaneous Historic and Forecast Sales By Regions
8.6. Others Historic and Forecast Sales By Regions
9. GLOBAL GENERIC INJECTABLES MARKET ANALYSIS BY GEOGRAPHY
9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
9.3.1 Overview, Historic and Forecast Data Sales Analysis
9.3.2 North America By Segment Sales Analysis
9.3.3 North America By Country Sales Analysis
9.3.4 United States Sales Analysis
9.3.5 Canada Sales Analysis
9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
9.4.1 Overview, Historic and Forecast Data Sales Analysis
9.4.2 Europe By Segment Sales Analysis
9.4.3 Europe By Country Sales Analysis
9.4.4 United Kingdom Sales Analysis
9.4.5 France Sales Analysis
9.4.6 Germany Sales Analysis
9.4.7 Italy Sales Analysis
9.4.8 Russia Sales Analysis
9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
9.5.1 Overview, Historic and Forecast Data Sales Analysis
9.5.2 Asia Pacific By Segment Sales Analysis
9.5.3 Asia Pacific By Country Sales Analysis
9.5.4 China Sales Analysis
9.5.5 India Sales Analysis
9.5.6 Japan Sales Analysis
9.5.7 South Korea Sales Analysis
9.5.8 Australia Sales Analysis
9.5.9 South East Asia Sales Analysis
9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
9.6.1 Overview, Historic and Forecast Data Sales Analysis
9.6.2 Latin America By Segment Sales Analysis
9.6.3 Latin America By Country Sales Analysis
9.6.4 Brazil Sales Analysis
9.6.5 Argentina Sales Analysis
9.6.6 Peru Sales Analysis
9.6.7 Chile Sales Analysis
9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
9.7.1 Overview, Historic and Forecast Data Sales Analysis
9.7.2 Middle East & Africa By Segment Sales Analysis
9.7.3 Middle East & Africa By Country Sales Analysis
9.7.4 Saudi Arabia Sales Analysis
9.7.5 UAE Sales Analysis
9.7.6 Israel Sales Analysis
9.7.7 South Africa Sales Analysis
9.7.8 Rest Of Middle East And Africa Sales Analysis
10. COMPETITIVE LANDSCAPE OF THE GENERIC INJECTABLES COMPANIES
10.1. Generic Injectables Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments
11. COMPANY PROFILES OF GENERIC INJECTABLES INDUSTRY
11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. AstraZeneca
11.3.1 Company Overview
11.3.2 Company Revenue
11.3.3 Products
11.3.4 Recent Developments
11.4. Baxter International Inc.
11.4.1 Company Overview
11.4.2 Company Revenue
11.4.3 Products
11.4.4 Recent Developments
11.5. Biocon
11.5.1 Company Overview
11.5.2 Company Revenue
11.5.3 Products
11.5.4 Recent Developments
11.6. Fresenius SE & Co. KGaA
11.6.1 Company Overview
11.6.2 Company Revenue
11.6.3 Products
11.6.4 Recent Developments
11.7. GlaxoSmithKline Plc
11.7.1 Company Overview
11.7.2 Company Revenue
11.7.3 Products
11.7.4 Recent Developments
11.8. Hikma Pharmaceuticals Plc
11.8.1 Company Overview
11.8.2 Company Revenue
11.8.3 Products
11.8.4 Recent Developments
11.9. Johnson & Johnson Services Inc.
11.9.1 Company Overview
11.9.2 Company Revenue
11.9.3 Products
11.9.4 Recent Developments
11.10. Lupin Ltd.
11.10.1 Company Overview
11.10.2 Company Revenue
11.10.3 Products
11.10.4 Recent Developments
11.11. Merck KGaA
11.11.1 Company Overview
11.11.2 Company Revenue
11.11.3 Products
11.11.4 Recent Developments
11.12. Mylan N.V.
11.12.1 Company Overview
11.12.2 Company Revenue
11.12.3 Products
11.12.4 Recent Developments
11.13. Novartis AG (Sandoz International GmbH)
11.13.1 Company Overview
11.13.2 Company Revenue
11.13.3 Products
11.13.4 Recent Developments
11.14. Pfizer Inc.
11.14.1 Company Overview
11.14.2 Company Revenue
11.14.3 Products
11.14.4 Recent Developments
11.15. Piramal Pharma Solutions
11.15.1 Company Overview
11.15.2 Company Revenue
11.15.3 Products
11.15.4 Recent Developments
11.16. Sun Pharmaceutical Industries Ltd.
11.16.1 Company Overview
11.16.2 Company Revenue
11.16.3 Products
11.16.4 Recent Developments
11.17. And Teva Pharmaceutical Industries Ltd
11.17.1 Company Overview
11.17.2 Company Revenue
11.17.3 Products
11.17.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies
